DOCSLIB.ORG

Myocardial Perfusion Imaging in Coronary Artery Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Myocardial Perfusion Imaging in Coronary Artery Disease Cor et Vasa Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/crvasa Přehledový článek | Review article Myocardial perfusion imaging in coronary artery disease Magdalena Kostkiewicza,b a Department of Cardiovascular Diseases, Jagiellonian University, Collegium Medicum, Hospital John Paul II, Krakow, Poland b Department of Nuclear Medicine, Hospital John Paul II, Jagiellonian University, Collegium Medicum, Krakow, Poland ARTICLE INFO SOUHRN Article history: Radionuklidové zobrazování perfuze myokardu (myocardial perfusion imaging, MPI) lze použít k prokázání Received: 22. 8. 2015 přítomnosti ischemické choroby srdeční (ICHS), stratifi kaci rizika i k vedení léčby pacientů s již potvrzeným Received in revised form: 26. 9. 2015 onemocněním. Uvedená metoda je schopna lokalizovat hemodynamicky významné stenózy koronárních Accepted: 28. 9. 2015 tepen i zhodnotit rozsah a závažnost jejich obstrukce podle přítomnosti a rozsahu defektů perfuze. Nor- Available online: 31. 10. 2015 mální výsledek MPI znamená nepřítomnost koronární obstrukce, a tedy i klinicky významného onemocnění. Předností vyšetření srdce metodou PET je oproti SPECT její vyšší prostorové a časové rozlišení i nižší radiační zátěž pacienta. Zdá se, že hybridní vyšetření srdce kombinací SPECT nebo PET s údaji z CT nabízí přesnější Klíčová slova: a spolehlivější diagnostické a prognostické informace o pacientech se středně vysokým rizikem rozvoje ICHS. Ischemická choroba srdeční V poslední době byl zaznamenán významný pokrok ve smyslu přesnější kvantifi kace průtoku krve myokar- PET dem a koronární průtokové rezervy. Několik studií rovněž prokázalo, že kombinace zobrazení apoptózy Radionuklidové zobrazování perfuze a tvorby matrixových metaloproteináz může být prospěšná při zobrazování nestabilních plátů a vyhledání myokardu skupin asymptomatických pacientů s vysokým rizikem, pro něž znamená vyšetření zobrazovací metodou SPECT největší přínos. © 2015, ČKS. Published by Elsevier sp. z o.o. All rights reserved. ABSTRACT Radionuclide myocardial perfusion imaging (MPI) can be used to demonstrate the presence of coronary heart disease and to risk stratify and guide management of patients with known disease. It has the ability to localise haemodynamically important coronary stenoses, and assess the extent and severity of coronary obstruction by the presence and extent of perfusion defects. A normal stress MPI indicates the absence of coronary obstruction and hence of clinically signifi cant disease. Cardiac PET has the advantage from SPECT of higher spatial and temporal resolution, and a decreased radiation exposure to patients. Hybrid cardiac Keywords: imaging combining SPECT or PET with CT data appears to offer superior diagnostic and prognostic informa- Coronary artery disease tion in patients with intermediate risk for CAD. A signifi cant progress in better quantifi cation of myocardial PET blood fl ow and coronary fl ow reserve has recently been seen. Also several studies have demonstrated that Radionuclide myocardial perfusion the combination of imaging apoptosis and matrix metalloproteinases production can help imaging vulner- imaging able plaque and identifying the group of high-risk asymptomatic patients who will benefi t most by an SPECT imaging procedure. Address: Magdalena Kostkiewicz, MD, PhD, Department of Cardiovascular Diseases, Jagiellonian University, Collegium Medicum, Hospital John Paul II, Krakow, Poland, e-mail: [email protected] DOI: 10.1016/j.crvasa.2015.09.010 Please cite this article as: M. Kostkiewicz, Myocardial perfusion imaging in coronary artery disease, Cor et Vasa 57 (2015) e446–e452 as published in the online version of the Cor et Vasa available at http://www.sciencedirect.com/science/article/pii/S0010865015001034 640_645_Prehledovy clanek Koskiewi.indd 640 2.12.2015 10:09:09 M. Kostkiewicz 641 Introduction Diagnosis and prognosis of obstructive CAD The accurate noninvasive diagnosis and functional eva- Exercise–ECG stress testing has an established role in asse- luation of coronary artery disease (CAD) is an important ssment of patients for the detection of occlusive CAD and step in selecting the appropriate management strategy. with known CAD; however, the progression from ECG- A complete assessment of CAD requires both anatomi- -based stress testing to current SPECT and PET technolo- cal and functional information. This can be obtained in gies has led to improvements in both diagnostic effi cacy a variety of ways and the common imaging techniques (sensitivity and specifi city for detecting CAD) and reso- overlap in their capabilities, particularly for the assess- lution (identifying the culprit lesion for chest pain and ment of myocardial viability, function, and coronary ana- myocardial ischemia) [3]. An additional advantage of tomy. Several noninvasive imaging options are available myocardial perfusion-based stress testing over ECG-only for the assessment of suspected or known coronary arte- testing is the applicability to patients with underlying ry disease and for a long-term prognosis of the disease. ECG abnormalities that mask dynamic ischemic ECG chan- Radionuclide tests occupy a central position within the ges. Nevertheless, many patients referred for stress tes- cardiac imaging modalities, and among them myocardial ting have functional limitations from pulmonary, ortho- perfusion imaging (MPI) has an obvious place because of pedic, peripheral vascular or neurologic conditions that its perfect validation for assessing myocardial perfusion. prevent suffi cient physical exercise. Ischemic ECG signals Patients with ECG abnormalities, poor exercise capacity, may be uninterpretable among patients with abnormal or intermediate pretest likelihood of disease according to baseline ST segment depression of >1 mm, electronic pa- the ECS guidelines, would be the best candidates for this cing, left bundle-branch block, or preexcitation pattern. noninvasive imaging [1]. These inadequacies as well as the limited sensitivity and The introduction of 201Tl myocardial perfusion imaging specifi city of ECG-based SPECT stress test have led to the as an adjunct to ECG treadmill studies in the mid-1970s development of alternate methods of stressors with phar- has evolved into the discipline of nuclear cardiology today macologic agents that either simulate exercise, such as an [2]. MPI provides direct assessment of myocardial perfu- adrenergic agent (dobutamine), or induce vasodilation sion and therefore has an important role in the diagnosis (adenosine or dipyridamole) [4]. of CAD in patients presenting with chest pain and inter- Myocardial uptake of a radiotracer used for MPI is mediate pretest likelihood. Techniques such as SPECT and a function of both delivery of the radiotracer to the cell PET currently allow evaluating occlusive coronary athero- surface (which is fl ow-dependent) and subsequent extrac- sclerosis by estimation of myocardial perfusion as well as tion and retention into the cell (which is dependent on cell effects of myocardial hypoperfusion on metabolic activity membrane integrity and viability). Intravascular radiotrac- and contractile function. An inducible perfusion abnor- er is extracted by myocardial tissue in proportion to blood mality indicates impaired perfusion reserve, which in turn fl ow. Thus, the same mechanisms leading to insuffi cient usually corresponds to epicardial coronary obstruction. oxygen delivery and subsequent ECG-detected myocardial Fig. 1 – Myocardial perfusion SPECT study viewed in slices and polar maps under stress and rest. Polar maps show perfusion, defect extent, wall thickening, and segmental scoring of perfusion defect severity. Stress perfusion defect in the apex and, majority of which signifi - cantly improves (reverses) in rest study (arrow). Masses of one or more stress defects and reversible portions of defects are automatically tabulated, along with stress total severity score. SSS – stress scores; SRS – rest scores; difference scores. Software – Emory Cardiac Toolbox. Department of Nuclear Medicine Hospital John Paul II Krakow, Poland. 640_645_Prehledovy clanek Koskiewi.indd 641 2.12.2015 10:09:10 642 Myocardial perfusion imaging in coronary artery disease ischemia on the treadmill can be assessed directly by in- 99mTc-sestamibi and 99mTc-tetrofosmin. Despite wide- terrogating regional myocardial perfusion. Regions of de- spread clinical use, those radiotracers are imperfect due creased myocardial uptake on SPECT and PET can then be partly to their nonlinear myocardial extraction at high correlated with specifi c coronary artery vascular territories fl ow rates and high initial hepatic uptake, which can and with a culprit atherosclerotic lesion responsible for make diffi cult interpretation of defects in the inferior the patient’s symptoms. A repeated radiotracer injection wall due to adjacent photon scatter. Radiotracers that and imaging after stress and at rest allows differentiating have minimal hepatic uptake or more rapid washout are between reversible and fi xed perfusion defects. Reversible continuously under investigation to ameliorate some of defects correlate with myocardial ischemia as seen by dy- these limitations [5]. namic ECG changes between resting and stress conditions. Typical protocols for a complete PET study for perfu- If the defect size decreases from rest to stress, this signifi es sion and viability in CAD include an initial rest myocar- hypoperfused but viable myocardium (hibernation), which dial perfusion image with 82Rb (rubidium) or 13N ammo-
Load more

Recommended publications
  • Radiosynthesis and in Vivo Evaluation of a 18F-Labelled Styryl-Benzoxazole Derivative for Β-Amyloid Targeting
    Author's Accepted Manuscript Radiosynthesis and in vivo Evaluation of a 18F- Labelled Styryl-Benzoxazole Derivative for β- Amyloid Targeting G.Ribeiro Morais, L. Gano, T. Kniess, R. Berg- mann, A. Abrunhosa, I. Santos, A. Paulo www.elsevier.com/locate/apradiso PII: S0969-8043(13)00292-3 DOI: http://dx.doi.org/10.1016/j.apradiso.2013.07.003 Reference: ARI6294 To appear in: Applied Radiation and Isotopes Received date: 9 January 2013 Revised date: 15 April 2013 Accepted date: 1 July 2013 Cite this article as: G.Ribeiro Morais, L. Gano, T. Kniess, R. Bergmann, A. Abrunhosa, I. Santos, A. Paulo, Radiosynthesis and in vivo Evaluation of a 18F- Labelled Styryl-Benzoxazole Derivative for β-Amyloid Targeting, Applied Radiation and Isotopes, http://dx.doi.org/10.1016/j.apradiso.2013.07.003 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Radiosynthesis and in vivo Evaluation of a 18F-Labelled Styryl-Benzoxazole Derivative for β-Amyloid Targeting G. Ribeiro Morais,1 L. Gano,1 T. Kniess,2 R. Bergmann,2 A. Abrunhosa,3 I. Santos,1 and A. Paulo1* 1Radiopharmaceutical Sciences Group, IST/ITN, Instituto Superior Técnico, Universidade Técnica de Lisboa, EN 10, 2686-953 Sacavem; 2Institute of Radiopharmacy, Helmholtz-Zentrum Dresden-Rossendorf e.V., POB 510119, D-01314 Dresden, Germany; 3Universidade Coimbra, ICNAS, Inst Nucl Sci Appl Saúde, P-3000 Coimbra, Portugal Corresponding e-mail: [email protected] Keywords: Alzheimer´s Disease/ β-Amyloid aggregation/ Molecular Imaging / Fluorine-18 Abstract The formation of β-amyloid deposits is considered a histopathological feature of Alzheimer´s disease (AD).
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Fluorine-18-Labeled Fluorescent Dyes for Dual-Mode Molecular Imaging
    molecules Review Fluorine-18-Labeled Fluorescent Dyes for Dual-Mode Molecular Imaging Maxime Munch 1,2,*, Benjamin H. Rotstein 1,2 and Gilles Ulrich 3 1 University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada; [email protected] 2 Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada 3 Institut de Chimie et Procédés pour l’Énergie, l’Environnement et la Santé (ICPEES), UMR CNRS 7515, École Européenne de Chimie, Polymères et Matériaux (ECPM), 25 rue Becquerel, CEDEX 02, 67087 Strasbourg, France; [email protected] * Correspondence: [email protected]; Tel.: +1-613-696-7000 Academic Editor: Emmanuel Gras Received: 30 November 2020; Accepted: 16 December 2020; Published: 21 December 2020 Abstract: Recent progress realized in the development of optical imaging (OPI) probes and devices has made this technique more and more affordable for imaging studies and fluorescence-guided surgery procedures. However, this imaging modality still suffers from a low depth of penetration, thus limiting its use to shallow tissues or endoscopy-based procedures. In contrast, positron emission tomography (PET) presents a high depth of penetration and the resulting signal is less attenuated, allowing for imaging in-depth tissues. Thus, association of these imaging techniques has the potential to push back the limits of each single modality. Recently, several research groups have been involved in the development of radiolabeled fluorophores with the aim of affording dual-mode PET/OPI probes used in preclinical imaging studies of diverse pathological conditions such as cancer, Alzheimer’s disease, or cardiovascular diseases. Among all the available PET-active radionuclides, 18F stands out as the most widely used for clinical imaging thanks to its advantageous characteristics (t1/2 = 109.77 min; 97% β+ emitter).
    [Show full text]
  • The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’S Disease—Review of Literature and Interesting Images
    diagnostics Review The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’s Disease—Review of Literature and Interesting Images Subapriya Suppiah 1,2 , Mellanie-Anne Didier 3,4 and Sobhan Vinjamuri 3,* 1 Centre for Diagnostic Nuclear Imaging, University Putra Malaysia, Serdang 43400, Selangor, Malaysia; [email protected] 2 Department of Imaging, Faculty of Medicine and Health Sciences, University Putra Malaysia, Serdang 43400, Selangor, Malaysia 3 The Royal Liverpool and Broadgreen University Hospitals NHS Trusts, Prescot St, Liverpool L7 8XP, UK; [email protected] 4 Section of Nuclear Medicine, Department of Surgery, Radiology, Anaesthesia & Intensive Care, The University Hospital of The West Indies, The University of The West Indies, Mona Campus, Kingston 7, Jamaica * Correspondence: [email protected] Received: 23 May 2019; Accepted: 21 June 2019; Published: 25 June 2019 Abstract: Amyloid imaging using positron emission tomography (PET) has an emerging role in the management of Alzheimer’s disease (AD). The basis of this imaging is grounded on the fact that the hallmark of AD is the histological detection of beta amyloid plaques (Aβ) at post mortem autopsy. Currently, there are three FDA approved amyloid radiotracers used in clinical practice. This review aims to take the readers through the array of various indications for performing amyloid PET imaging in the management of AD, particularly using 18F-labelled radiopharmaceuticals. We elaborate on PET amyloid scan interpretation techniques, their limitations and potential improved specificity provided by interpretation done in tandem with genetic data such as apolipiprotein E (APO) 4 carrier status in sporadic cases and molecular information (e.g., cerebral spinal fluid (CSF) amyloid levels).
    [Show full text]
  • Radiotracer Imaging of Peripheral Vascular Disease
    CONTINUING EDUCATION Reprinted from The Journal of Nuclear Medicine Radiotracer Imaging of Peripheral Vascular Disease Mitchel R. Stacy1, Wunan Zhou1, and Albert J. Sinusas1,2 1Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut; and 2Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut CE credit: For CE credit, you can access the test for this article, as well as additional JNMT CE tests, online at https://www.snmmilearningcenter.org. Complete the test online no later than September 2018. Your online test will be scored immediately. You may make 3 attempts to pass the test and must answer 80% of the questions correctly to receive 1.0 CEH (Continuing Education Hour) credit. SNMMI members will have their CEH credit added to their VOICE transcript automatically; nonmembers will be able to print out a CE certificate upon successfully completing the test. The online test is free to SNMMI members; nonmembers must pay $15.00 by credit card when logging onto the website to take the test. limb ischemia that can lead to life-altering claudication, non- Peripheral vascular disease (PVD) is an atherosclerotic disease healing ulcers, limb amputation, and, in severe cases, affecting the lower extremities, resulting in skeletal muscle death (2). Despite these numbers and a close association ischemia, intermittent claudication, and, in more severe stages of with coronary artery disease, PVD still remains a relatively disease, limb amputation and death. The evaluation of therapy underdiagnosed disease (4). in this patient population can be challenging, as the standard clinical indices are insensitive to assessment of regional Several techniques have been used for the evaluation and alterations in skeletal muscle physiology.
    [Show full text]
  • Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643 and 11C-RO6924963 As Novel Radiotracers for Imaging Aggregated Tau in AD
    Journal of Nuclear Medicine, published on September 28, 2017 as doi:10.2967/jnumed.117.196741 Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643 and 11C-RO6924963 as Novel Radiotracers for Imaging Aggregated Tau in Alzheimer’s Disease with Positron Emission Tomography Michael Honer1, Luca Gobbi1, Henner Knust1, Hiroto Kuwabara2,3, Dieter Muri1, Matthias Koerner1, Heather Valentine2,3, Robert F. Dannals2, Dean F. Wong2,3,4,5,6, Edilio Borroni1 1Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland 2Russell H. Morgan Department of Radiology, Division of Nuclear Medicine – PET Center, The Johns Hopkins University School of Medicine, Baltimore 3Section of High Resolution Brain PET, Division of Nuclear Medicine, The Johns Hopkins University School of Medicine, Baltimore 4Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore 5Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore 6Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore Corresponding author: Dr. Michael Honer Pharma Research and Early Development (pRED) Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel, Switzerland E-mail: [email protected] Running foot line: PET imaging of tau Abstract Tau aggregates and amyloid-beta (Aβ) plaques are key histopathological features in Alzheimer‘s disease (AD) and are considered as targets for therapeutic intervention as well as biomarkers for diagnostic in vivo imaging agents. This study describes the preclinical in vitro and in vivo characterization of the 3 novel compounds RO6958948, RO6931643 and RO6924963 that bind specifically to tau aggregates and have the potential to become positron emission tomography (PET) tracers for future human use.
    [Show full text]
  • Principles and Practice of PET/CT
    EANM® Eu ne rope edici an Association of Nuclear M Publications · Brochures Principles and Practice of PET/CT Part 2 A Technologist‘s Guide Produced with the kind Support of Editors Giorgio Testanera Wim J.M. van den Broek Rozzano (MI), Italy Nijmegen, The Netherlands Contributors Ambrosini, Valentina (Italy) Kaufmann, Philipp A. (Switzerland) Beijer, Emiel (The Netherlands) Krause, Bernd J. (Germany) Bomanji, Jamshed B. (UK) Królicki, Leszek (Poland) Booij, Jan (The Netherlands) Kunikowska, Jolanta (Poland) Bozkurt, Murat Fani (Turkey) Mottaghy, Felix Manuel (Germany) Carreras Delgado, José L. (Spain) Nobili, Flavio (Italy) Chiti, Arturo (Italy) Oyen, Wim J.G. (The Netherlands) Darcourt, Jacques (France) Pagani, Marco (Italy) Decristoforo, Clemens (Austria) Papathanasiou, Nikolaos D. (Greece) Delgado-Bolton, Roberto C. (Spain) Petyt, Gregory (France) Dennan, Suzanne (Ireland) Poepperl, Gabriele (Germany) Elsinga, Philip H. (The Netherlands) Prompers, Leonne (The Netherlands) Fanti, Stefano (Italy) Schwarzenboeck, Sarah (Germany) Gaemperli, Oliver (Switzerland) Semah, Franck (France) Giammarile, Francesco (France) Souvatzoglou, Michael (Germany) Giurgola, Francesca (Italy) Tarullo, Gianluca (Italy) Grugni, Stefano (Italy) Tatsch, Klaus (Germany) Halders, Servé (The Netherlands) Testanera, Giorgio (Italy) Hanin, François-Xavier (Belgium) Urbach, Christian (The Netherlands) Houzard, Claire (France) Vaccaro, Ilaria (Italy) Jamar, François (Belgium) 2 Contents Foreword 5 Suzanne Dennan Introduction 6 Wim van den Broek and Giorgio Testanera Chapter 1 – Principles of PET radiochemistry 8 1.1 Introduction to PET radiochemistry 8 Clemens Decristoforo 1.2 Common practice in PET tracer quality control 10 Gianluca Tarullo and Stefano Grugni 1.3 Basics of 18F and 11C radiopharmaceutical chemistry 18 Philip H. Elsinga EANM 1.4 [18F]FDG synthesis 26 Francesca Giurgola, Ilaria Vaccaro and Giorgio Testanera 1.5 68Ga-peptide tracers 32 Jamshed B.
    [Show full text]
  • New Protein Deposition Tracers in the Pipeline Aleksandar Jovalekic, Norman Koglin, Andre Mueller and Andrew W
    Jovalekic et al. EJNMMI Radiopharmacy and Chemistry (2016) 1:11 EJNMMI Radiopharmacy DOI 10.1186/s41181-016-0015-3 and Chemistry REVIEW Open Access New protein deposition tracers in the pipeline Aleksandar Jovalekic, Norman Koglin, Andre Mueller and Andrew W. Stephens* * Correspondence: [email protected] Abstract Piramal Imaging GmbH, Tegeler Straße 6-7, 13353 Berlin, Germany Traditional nuclear medicine ligands were designed to target cellular receptors or transporters with a binding pocket and a defined structure–activity relationship. More recently, tracers have been developed to target pathological protein aggregations, which have less well-defined structure–activity relationships. Aggregations of proteins such as tau, α-synuclein, and β-amyloid (Aβ) have been identified in neurodegenerative diseases, including Alzheimer’s disease (AD) and other dementias, and Parkinson’sdisease(PD). Indeed, Aβ deposition is a hallmark of AD, and detection methods have evolved from coloured dyes to modern 18F-labelled positron emission tomography (PET) tracers. Such tracers are becoming increasingly established in routine clinical practice for evaluation of Aβ neuritic plaque density in the brains of adults who are being evaluated for AD and other causes of cognitive impairment. While similar in structure, there are key differences between the available compounds in terms of dosing/dosimetry, pharmacokinetics, and interpretation of visual reads. In the future, quantification of Aβ-PET may further improve its utility. Tracers are now being developed for evaluation of tau protein, which is associated with decreased cognitive function and neurodegenerative changes in AD, and is implicated in the pathogenesis of other neurodegenerative diseases. While no compound has yet been approved for tau imaging in clinical use, it is a very active area of research.
    [Show full text]
  • Non-Oncologic Applications of PET/CT and PET/MR In
    J of Nuclear Medicine Technology, first published online November 10, 2017 as doi:10.2967/jnmt.117.198663 Non‐oncologic Applications of PET/CT and PET/MR in Musculoskeletal, Orthopedic, and Rheumatologic Imaging: General Considerations, Techniques, and Radiopharmaceuticals Running title: PET in Musculoskeletal and Rheumatologic Imaging Authors Ali Gholamrezanezhad1, 2 Kyle Basques3 Ali Batouli4 Mojtaba Olyaie4 George Matcuk1 Abass Alavi5 Hossein Jadvar6 1. Division of Musculoskeletal Imaging. Department of Radiology. Keck School of Medicine. University of Southern California (USC). CA. USA 2. Corresponding author: Division of Musculoskeletal Imaging. Department of Radiology. Keck School of Medicine. University of Southern California (USC). 1520 San Pablo Street, Los Angeles, CA 90033. Phone: +1(443)839‐7134. Email: [email protected] 3. Division of Musculoskeletal Imaging. Department of Radiology. University Hospitals of Cleveland. Case Western Reserve University. Cleveland. OH. USA. 4. Department of Radiology. Allegheny General Hospital. Pittsburgh. PA. USA. 5. Division of Nuclear Medicine. Department of Radiology. Hospital of the University of Pennsylvania, Philadelphia, PA. USA. 6. Division of Nuclear Medicine. Department of Radiology. Keck School of Medicine. University of Southern California (USC). CA. USA. 1 Abstract Positron Emission Tomography (PET) is often underutilized in the field of musculoskeletal imaging, with key reasons including the excellent performance of conventional musculoskeletal MRI, the limited spatial resolution of PET, and the lack of reimbursement for PET for non‐oncologic musculoskeletal indications. However, with improvements in PET/CT and PET/MR imaging over the last decade as well as an increased understanding of the pathophysiology of musculoskeletal diseases, there is an emerging potential for PET as a primary or complementary modality in the management of rheumatologic and orthopedic patients.
    [Show full text]
  • FAZA and [18F]FDG in a Murine Tumor Bearing Model
    J Pharm Pharm Sci (www.cspsCanada.org) 21, 32s – 47s, 2018 Positron Emission Tomography (PET) and Pharmacokinetics: Classical Blood Sampling Versus Image-Derived Analysis of [18F]FAZA and [18F]FDG in a Murine Tumor Bearing Model Hans-Soenke Jans1, Xiao-Hong Yang1, Dion R Brocks2, Piyush Kumar1, Melinda Wuest1, and Leonard I Wiebe1,2 1Department of Oncology, Faculty of Medicine and 2Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada Received, February 6, 2018; Revised, March 4, 2018; Accepted, April 17, 2018; Published, April 20, 2018. ABSTRACT - Purpose: Pharmacokinetic (PK) data are generally derived from blood samples withdrawn serially over a defined period after dosing. In small animals, blood sampling after dosing presents technical difficulties, particularly when short time intervals and frequent sampling are required. Positron emission tomography (PET) is a non-invasive functional imaging technique that can provide semi-quantitative temporal data for defined volume regions of interest (vROI), to support kinetic analyses in blood and other tissues. The application of preclinical small-animal PET to determine and compare PK parameters for [18F]FDG and [18F]FAZA, radiopharmaceuticals used clinically for assessing glucose metabolism and hypoxic fractions, respectively, in the same mammary EMT6 tumor-bearing mouse model, is reported here. Methods: Two study groups were used: normal BALB/c mice under isoflurane anesthesia were intravenously injected with either [18F]FDG or [18F]FAZA. For the first group, blood-sampling by tail artery puncture was used to collect blood samples which were then analyzed with Radio-microTLC. Dynamic PET experiments were performed with the second group of mice and analyzed for blood input function and tumor uptake utilizing a modified two compartment kinetic model.
    [Show full text]
  • I-124 Imaging and Dosimetry Russ Kuker University of Miami
    Florida International University FIU Digital Commons HWCOM Faculty Publications Herbert Wertheim College of Medicine 2017 I-124 Imaging and Dosimetry Russ Kuker University of Miami Manuel Sztejnberg National Atomic Energy Commission of Argentina Seza Gulec Herbert Wertheim College of Medicine, Florida International University, [email protected] Follow this and additional works at: https://digitalcommons.fiu.edu/com_facpub Part of the Medicine and Health Sciences Commons Recommended Citation Kuker, Russ; Sztejnberg, Manuel; and Gulec, Seza, "I-124 Imaging and Dosimetry" (2017). HWCOM Faculty Publications. 110. https://digitalcommons.fiu.edu/com_facpub/110 This work is brought to you for free and open access by the Herbert Wertheim College of Medicine at FIU Digital Commons. It has been accepted for inclusion in HWCOM Faculty Publications by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. Review Mol Imaging Radionucl Ther 2017;26(Suppl 1):66-73 DOI:10.4274/2017.26.suppl.07 I-124 Imaging and Dosimetry I-124 Görüntüleme ve Dozimetri Russ Kuker1, Manuel Sztejnberg2, Seza Gulec, MD, FACS3 1University of Miami Miller School of Medicine, Department of Radiology, Miami, USA 2National Atomic Energy Commission of Argentina, Division of Instrumentation and Dosimetry, Buenos Aires, Argentina 3Florida International University Herbert Wertheim College of Medicine, Departments of Surgery and Nuclear Medicine, Miami, USA Abstract Although radioactive iodine imaging and therapy are one of the earliest applications of theranostics, there still remain a number of unresolved clinical questions as to the optimization of diagnostic techniques and dosimetry protocols. I-124 as a positron emission tomography (PET) radiotracer has the potential to improve the current clinical practice in the diagnosis and treatment of differentiated thyroid cancer.
    [Show full text]
  • Review Article Searching for Novel PET Radiotracers: Imaging Cardiac Perfusion, Metabolism and Inflammation
    Am J Nucl Med Mol Imaging 2018;8(3):200-227 www.ajnmmi.us /ISSN:2160-8407/ajnmmi0079469 Review Article Searching for novel PET radiotracers: imaging cardiac perfusion, metabolism and inflammation Caitlund Q Davidson1, Christopher P Phenix2, TC Tai3, Neelam Khaper1,4, Simon J Lees1,4 1Department of Biology, Lakehead University, Thunder Bay, Ontario, Canada; 2Department of Chemistry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; 3Medical Sciences Division, Northern Ontario School of Medicine, Laurentian University, Sudbury, Ontario, Canada; 4Medical Sciences Division, Northern Ontario School of Medicine, Lakehead University, Thunder Bay, Ontario, Canada Received April 3, 2018; Accepted May 20, 2018; Epub June 5, 2018; Published June 15, 2018 Abstract: Advances in medical imaging technology have led to an increased demand for radiopharmaceuticals for early and accurate diagnosis of cardiac function and diseased states. Myocardial perfusion, metabolism, and hy- poxia positron emission tomography (PET) imaging radiotracers for detection of cardiac disease lack specificity for targeting inflammation that can be an early indicator of cardiac disease. Inflammation can occur at all stages of car- diac disease and currently, 18F-fluorodeoxyglucose (FDG), a glucose analog, is the standard for detecting myocardial inflammation. 18F-FDG has many ideal characteristics of a radiotracer but lacks the ability to differentiate between glucose uptake in normal cardiomyocytes and inflammatory cells. Developing a PET radiotracer that differentiates not only between inflammatory cells and normal cardiomyocytes, but between types of immune cells involved in inflammation would be ideal. This article reviews current PET radiotracers used in cardiac imaging, their limitations, and potential radiotracer candidates for imaging cardiac inflammation in early stages of development of acute and chronic cardiac diseases.
    [Show full text]